SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Feb 22, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Feb. 22, 2017 · CIK: 0001506251 · Accession: 0000000000-17-005954
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-216030
Letter
Mail Stop 4546 February 21 , 2017 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016
Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed February 10, 2017 File No. 333-216030
Dear Mr. Holubiak :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551 -5019 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 February 21 , 2017 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed February 10, 2017 File No. 333-216030 Dear Mr. Holubiak : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551 -5019 with any questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Erica B. Jackson , Esq. Wyrick Robbins Yates & Ponton LLP